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The top 10 research 
priorities in cystic fibrosis 
developed by a partnership 
between people with CF and 
healthcare providers
AbstrAct 
There remain many treatment uncertainties 
in cystic fibrosis (CF). With limited resources, 
research should focus on questions which 
are most important to the CF community. 
We conducted a James Lind Alliance Priority 
Setting Partnership in CF. Research questions 
were elicited and then prioritised in successive 
surveys. A workshop agreed the final top 
10. Online methods avoided cross infection 
and widened participation. The elicitation 
survey had 482 respondents (1080 questions) 
and prioritisation survey 677 respondents. 
Participants were drawn equally from the 
patient and clinical communities globally. We 
have achieved a consensus on 10 research 
priorities which will be attractive to funders.
IntroductIon
Therapies targeting the basic defect of cystic 
fibrosis (CF) are now available in the clinic, 
with more in development.1 However, 
conventional therapies for persistent airway 
infection and pancreatic malabsorption 
are still required and there remain many 
treatment uncertainties, which have yet 
to be clarified through well designed and 
adequately powered clinical trials.2
Both the Patient-Centered Outcomes 
Research Institute, in the USA, and the 
National Institute for Health Research 
(NIHR), in the UK, support patient 
involvement and ‘co-production’ of 
research.3 However, there has been no 
systematic and inclusive dialogue between 
clinicians, patients and parents about 
priorities for clinical research in CF. 
Face-to-face contact between patients is 
precluded due to risk of transmission of 
organisms such as Pseudomonas aerugi-
nosa, providing a challenge to consultative 
exercises involving patients with CF.4
The NIHR James Lind Alliance (JLA) 
supports Priority Setting Partnerships 
which bring patients, carers and clinicians 
together to prioritise research questions. 
Outcomes from JLA Priority Setting Part-
nerships have a track record of attracting 
significant research funding.5 We 
conducted a JLA Priority Setting Partner-
ship in CF to identify the key treatment 
uncertainties for the CF community and 
produce the top 10 research questions for 
treatment and management of CF.
Methods
Our Priority Setting Partnership took 
place in March 2016–January 2017. We 
published our protocol before commencing 
(http:// eprints. nottingham. ac. uk/ 35223/). 
We followed JLA methodology,6 adapting 
the process using online methods to avoid 
risk of cross infection. Our steering group 
was selected to include lay members (two 
people with CF and two parents) and 
professionals from each discipline: two 
respiratory paediatricians, respiratory 
physician, physiotherapist, dietitian, nurse, 
pharmacist, clinical psychologist and social 
worker. We also included a specialist 
commissioner, UK Cystic Fibrosis Trust 
representative and four academics (system-
atic reviewer, qualitative researcher, project 
manager and academic clinical fellow).
From March to June 2016, we conducted 
the first of two online surveys (Survey 
Monkey). The elicitation survey requested 
respondent demographics and asked a single 
question ‘What question on Cystic Fibrosis 
would you like to see answered by research?’ 
Respondents could submit up to five ques-
tions. The survey was advertised through 
professional groups, clinic posters and our 
bespoke Twitter account (@questionCF).
Two researchers (NR and SS) inde-
pendently reviewed all questions submitted 
with adjudication by the steering group. 
Non-questions and questions unrelated to 
treatment were removed. We conducted a 
systematic review of evidence gaps in CF7 and 
excluded any questions already answered. 
Where several questions addressed the same 
issue, they were consolidated into a single 
‘standardised question’.
The steering group undertook a Delphi8 
assessment of the standardised questions 
to produce a shortlist for the prioritisation 
research letter
table 1 Demographic characteristics of respondents to elicitation survey and prioritisation 
survey. Of the 513 responses to elicitation survey, 31 were from respondents who completed 
the survey more than once (482 individual respondents). Data are presented as number (%) or 
median (range)
characteristic
elicitation survey
(n=482)
Prioritisation survey
(n=677)
Male 111 (23.0) 153 (22.6)
Female 315 (65.4) 454 (67.1)
Did not answer 56 (11.6) 70 (10.3)
Median age (range) 42 (6–82) 41 (6–82)
category of respondent
Lay persons 224 (46.5) 314 (46.4)
  Person with cystic fibrosis 95 (19.7) 121 (17.9)
  Parent of person with cystic fibrosis 105 (21.8) 160 (23.6)
  Family and friends 24 (5.0) 33 (4,9)
Professionals 211 (43.8) 303 (44.8)
  Medical doctor 61 (12.7) 85 (12.6)
  Nurse 22 (4.6) 32 (4.7)
  Physiotherapist 49 (10.2) 65 (9.6)
  Dietitian 31 (6.4) 41 (6.1)
  Pharmacist 6 (1.2) 18 (2.7)
  Social worker 7 (1.5) 16 (2.4)
  Non-clinical researcher 10 (2.1) 7 (1.0)
  Psychologist 21 (4.4) 38 (5.6)
  Other 4 (0.8) 1 (0.1)
Did not answer 47 (9.8) 60 (8.9)
country
  UK 249 (51.7) 474 (70.0)
  USA and Canada 91 (18.9) 70 (10.3)
  Rest of Europe 45 (9.3) 42 (6.2)
  Australia and New Zealand 35 (7.3) 22 (3.2)
  Other 5 (1.0) 5 (0.7)
Did not answer 57 (11.8) 64 (9.5)
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survey. This allowed participants to 
rank their top 10 questions (September–
November 2016). The prioritisation 
survey was advertised through Twitter and 
by emailing participants who completed the 
elicitation survey.
The top 20 questions chosen through the 
prioritisation survey were then discussed at a 
workshop in January 2017. Lay and profes-
sional participants (recruited through the 
prioritisation survey), all with equal voice, 
led by three independent JLA facilitators, 
selected the final top 10 research priorities, 
through a process of small group discussion 
and plenary voting. Patient representatives 
joined remotely from home and hospital 
using video conferencing.
results
We had 513 replies to the elicitation survey, 
of which 31 completed the survey more 
than once, leaving 482 respondents who 
submitted 1080 questions. Table 1 shows 
the demographics of elicitation survey 
respondents. There were 224 (46.5%) lay 
respondents, 211 (43.8%) professionals and 
47 (9.8%) were unknown. Just over half 
were from the UK, with submissions from 
23 countries in total.
Figure 1A describes how the questions 
were sorted and refined. There were 704 
treatment and management questions which 
were combined into 127 standardised ques-
tions. Following the Delphi process, 71 ques-
tions were taken forward for prioritisation. 
The prioritisation survey was completed 
by 677 respondents (see table 1 for demo-
graphics). The final top 10 questions are 
shown in figure  1B.
dIscussIon
We have undertaken the first JLA Priority 
Setting Partnership in CF, with equal 
numbers of participants from the patient 
and clinical communities. We have produced 
a top 10 list of clinical research questions 
in CF, which will be attractive to both 
researchers and funders.
There has been little previous work of this 
kind. The Italian Patient-Centered Outcomes 
CF Research Group canvassed opinion from 
12 clinical researchers and eight ‘expert 
stakeholders’.9 This exercise prioritised five 
topics: transplantation, Cystic Fibrosis Trans-
membrane Conductance Regulator (CFTR) 
modulators, P. aeruginosa, Burkholderia 
cepacia and allergic bronchopulmonary 
aspergillosis. The management of infection 
in CF also featured in our top 10—non-tu-
berculous mycobacteria (Q3) and P. aerugi-
nosa (Q10). Infection with P. aeruginosa has 
previously been shown to be a great concern 
to parents and patients with CF.10 Surpris-
ingly, questions on CFTR modulators were 
absent from our top 10. Respondents might 
assume this research will progress whether 
or not prioritised.
The strength of our study is our global 
reach and the large numbers of respond-
ents, representing the whole CF commu-
nity. Online surveys give less granular data 
than approaches such as focus groups. An 
Figure 1 (A) James Lind Alliance Priority Setting Partnership in CF. Flow chart of submitted questions, showing the process for selecting the final top 
20. (B) The top 10 questions for clinical research in cystic fibrosis.
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alternative approach to ours—focus groups, 
using video conferencing—would also avoid 
cross infection. Key aspects of our robust 
methodology were a representative steering 
committee, a systematic review of research 
gaps and having two researchers inde-
pendently processing questions. Our expe-
rience of using online surveys, promotion 
through social media and video conferencing 
may be useful to other patient engagement 
exercises in respiratory medicine and beyond 
where face-to-face meetings are restricted by 
infection control, geography or frailty of 
participants. The US CF Foundation ‘Insight 
CF’ engagement programme has adopted a 
similar approach to registry-based research.
The items on the top 10 list are not 
prescriptive, rather they allow research 
groups to formulate a testable hypothesis 
with the appropriate study design. We are 
in discussion with the NIHR Evaluation, 
Trials and Studies Coordinating Centre 
about topics from our top 10, suitable for 
NIHR-commissioned research. We hope 
that this exercise will invigorate research 
in areas of shared importance to both the 
patient and the clinical community and 
demonstrate the value of involving the 
whole CF community in all steps of the 
research pathway.
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